- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03456609
Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(BCS) With Digestive Tract .
The Efficacy and Safety of Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(Palliative Care) With Digestive Tract Were Prospectively, Randomized Blind, Multicenter Clinical Trials
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Factors for the purpose of this study by observing theShenqifuzheng injection before and after treatment in patients with carcinoma due to fatigue scale scores, the classification of syndromes, the quality of life score changes and related laboratory index, evaluation factors ginseng and astragalus injection on the digestive tract tumor (chemotherapy) in patients with cancer-related fatigue and quality of life improved efficacy and safety. The experimental group was randomly divided into 2 groups, experimental group Shenqifuzheng injection of 500 ml. The control group was 0.9% sodium chloride injection, 500ml, intravenous drip, 1 time daily, 14 days for continuous use, 7 days of rest, and 1 treatment for each 21 days, and 2 courses were observed. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment.
Main efficacy evaluation indexes before and after treatment for cancer-related fatigue rating - adopting the Piper fatigue scale revised Chinese version, compare the experimental group and the control group before and after treatment cancer-related fatigue rating difference have differences. Secondary efficacy evaluation index to compare the ECOG score difference before and after the treatment, the quality of life score difference before and after the treatment, TCM syndrome curative effect, single symptom curative effect of immune function, tumors had curative effect (if any) and chemotherapy completion. Safety assessment includes the observation of vital signs, blood routine, urinary routine, routine stool, liver function, renal function, electrocardiogram examination, and adverse reactions during the treatment.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana
- Reclutamiento
- First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
-
Contacto:
- lin lizhu, Dr.
- Número de teléfono: 13501505588
- Correo electrónico: 13501505588@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 1. Patients with gastric cancer, esophageal cancer or colorectal cancer diagnosed by pathology or cytology;
- 2. Diagnostic criteria for cancer-related fatigue;
- 3. Syndrome differentiation of Chinese medicine is a syndrome of lung temper;
- 4. Estimated survival over 3 months;
- 5. ECOG score is less than or equal to 3
- 6. Age 18 ~ 80 years old;
- 7. Non-surgical indications or reluctance to operate the surgical treatment;
- 8. 70 g/L or higher HGB;
- 9. Stop and chemotherapy for more than 1 month;
- 10. The patient is willing to accept the treatment of the programme, and can follow the doctor's advice to take the medicine and comply with the patient.
Exclusion Criteria:
1. Any situation that may hinder the subject from completing the clinical trial, including but not limited to serious, uncontrollable organic disease or infection:
- clinically significant cardiovascular diseases, such as heart failure (NYHA III-IV), uncontrolled coronary heart disease, cardiomyopathy, arrhythmia, etc.
- serious clinical infection of activity (greater than 3 degrees nci-ctcae 4.03)
- uncontrolled hypertension (systolic pressure is greater than 160 mmHg or diastolic pressure is greater than 100 mmHg, despite the best drug treatment);
- severe liver and kidney function abnormality (blood creatinine is greater than 1.5 times ULN; ALT or AST is greater than 5 times ULN; Bilirubin is greater than 1.5 times ULN.
- other diseases that need to be controlled: pulmonary congestion, etc.
- 2. Patients with symptoms, uncontrollable nerves, mental illness or mental disorders;
- 3. Compliance.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: shenqifuzheng
|
500ml shenqifuzheng daily(at day 1-14 and day22-36)through intravenous infusion.
|
|
Comparador de placebos: 0.9%sodium chloride
|
500ml sodium chloride(0.9%)daily(at
day 1-14 and day22-36)through intravenous infusion.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Piper Fatigue Scale(PFS)
Periodo de tiempo: 42 days
|
Change From Baseline in Piper Fatigue Scores at 42 days
|
42 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: lin lizhu, Dr., First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- livzon-sqfz-BCS
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre shenqifuzheng injection
-
Livzon Pharmaceutical Group Inc.The First Affiliated Hospital, Guangzhou University of Traditional Chinese...Desconocido
-
Sargodha Medical CollegeTerminadoEscalofríos perioperatorios bajo anestesia espinalPakistán